Sanofi announced today that it is acquiring Florida-based VaxDesign for $60 M dollars. VaxDesign develops and manufactures in vitro models of the human immune system, known as Modular IMmune In-vitro Construct technology (say that fast 3x).
Sanofi says the technology will enable it to more rapidly and accurately screen new drug candidates prior to phase I to facilitate selection of "the best". This should save big bucks in late stages by weeding out pretenders earlier in the process.
MIMIC (now say that fast 3x - better) "is the most advanced platform in the field", said Michel DeWilde, Sanofi's Senior VP of R&D. Reportedly, MIMIC reproduced Sanofi's own clinical data and will have particular application to the development of vaccines. See Fierce Biotech.
Posted by Bruce Lehr September 28th 2010.